SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-23-052749
Filing Date
2023-11-13
Accepted
2023-11-13 08:48:22
Documents
75
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ef20012451_10q.htm   iXBRL 10-Q 1612869
2 EXHIBIT 31.1 ef20012451_ex31-1.htm EX-31.1 8709
3 EXHIBIT 31.2 ef20012451_ex31-2.htm EX-31.2 7885
4 EXHIBIT 32.1 ef20012451_ex32-1.htm EX-32.1 7068
  Complete submission text file 0001140361-23-052749.txt   7710060

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ocup-20230930.xsd EX-101.SCH 66695
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ocup-20230930_cal.xml EX-101.CAL 41353
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ocup-20230930_def.xml EX-101.DEF 312118
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20230930_lab.xml EX-101.LAB 738095
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20230930_pre.xml EX-101.PRE 460609
69 EXTRACTED XBRL INSTANCE DOCUMENT ef20012451_10q_htm.xml XML 1188229
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 231395512
SIC: 2834 Pharmaceutical Preparations